Gilead Sciences (GILD) is nearing a deal to buy biotech Immunomedics Inc for more than $20 billion, says the Wall Street Journal, which …
Shares in biopharma Immunomedics (IMMU) soared 29% in Wednesday’s after-market trading following an early FDA approval for Trodelvy (sacituzumab govitecan) in triple-negative breast …
Biotech stocks require only a few select indicators to send a share price soaring, or conversely, to cause it to tumble mercilessly down …
Immu-132 continues to have strong efficacy in centrally-reviewed data at SABCS, says Cowen’s Phil Nadeau.
Immunomedics, Inc. (NASDAQ:IMMU) left investors worried about its cancer asset IMMU-132 after revealing an abstract at yesterday’s annual San Antonio Breast Cancer Symposium …
Cowen places more importance on ORR strength than reduction in OS for IMMU’s prospects for a green light.
